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Background
Since 2006, enzyme replacement therapy (ERT) has been
available as a treatment for patients with Pompe disease.
ERT has shown efficacy concerning muscle strength and
pulmonary function in adult patients. However, no data
on the effect of ERT on the survival of adult patients
are currently available. Our objective was to assess the
effect of ERT on survival in adult patients with Pompe
disease.
Methods
Data were collected as part of an international observa-
tional study conducted between 2002 and 2011 in which
patients were followed on an annual basis. Time depen-
dent covariate Cox’s proportional hazards models were
used for univariate and multivariate analyses of the risk
of death. Patients who discontinued treatment were cen-
sored at the time of discontinuation. Additionally, we
used an ‘intention to treat’ approach.
Results
Overall, 283 adult patients with a median age of 48 years
(range, 19-81 years) were included in the study. Seventy-
two percent of the patients started ERT at some time
during follow-up and 28% never received ERT. During
follow-up (median, 6 years; range, 0.04 to 9 years), 46
patients died, 28 (61%) of whom had never received ERT.
After adjustment for age, gender, country of residence,
and disease severity (based on wheelchair and ventilator
use), ERT was positively associated with survival (hazard
ratio 0.41, CI 95 % 0.19-0.87). The hazard ratio for ERT
in the multivariable analyses of the intention to treat
approach was 0.33 (CI 95 % 0.15-0.73).
Conclusion
Our prospective study provides novel data on the posi-
tive effect that ERT has on survival in adults with
Pompe disease. Given the fact that ERT was only regis-
tered in 2006, this may be considered as a very promis-
ing finding.
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